Johnson & Johnson (JNJ)
MedTech To Drive Johnson & Johnson's Q2?
Johnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively.
J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
2 Healthcare Stocks to Buy Hand Over Fist This Month
Johnson & Johnson and Medtronic are healthcare leaders that have faced their share of issues in recent years. Still, both companies have the innovative capabilities and expertise to succeed in the industry in the long run.
3 Key Earnings Reports to Watch Next Week
With the 2024 Q2 earnings season kicking into a much higher gear next week, there are several reports investors should keep on their radars, including these three.
Unlocking Q2 Potential of Johnson & Johnson (JNJ): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Johnson & Johnson (JNJ) for the quarter ended June 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
3 Essential Stocks for Building a Recession-Proof Portfolio
Recession-proof stocks offer investors a safe harbor to shield their portfolios from downside risk. The stock market has cooled off following its AI-powered surge for the last two years.
Johnson & Johnson Q2 Earnings Preview: Scrutinizing Its Earnings Quality
Johnson & Johnson will announce its Q2 2024 results on Wednesday, July 17 before the market opens. In this update, I share what to expect from JNJ's Q2 results and put previous results into perspective. In the main part of the article, I will take a close look at JNJ's earnings adjustments, amid the significant deviation from GAAP earnings (+46% median since 2014).
3 Undervalued Stocks Set to Outperform the Market in 2024
During stock investing, having a list of the top undervalued stocks can offer lucrative opportunities for value growth and portfolio stability. Here are three stocks whose intrinsic value exceeds their current market price, promising potential gains as the market corrects itself.
AI picks 3 must-have dividend stocks for 2024 H2
In an era where some investors prioritize stable income and reliable returns, artificial intelligence (AI) has identified three standout dividend stocks poised to shine in the latter half of 2024.
7 Diversified Income Powerhouses for Lifelong Cash Flow
Diversified income stocks are a smart choice for investors seeking lifelong cash flow. They offer a reliable stream of income from multiple sources and provide stability and growth potential in any market condition.
Johnson & Johnson: Remaining A Buy Despite Remaining Risks
Johnson & Johnson reported solid first quarter results and is also expecting mid-single digit growth for the full year. The company is facing risks right now, especially from the litigations due to the talc products, and breaking the support line is also a rather bearish sign. But the stock seems slightly undervalued at this point, and Johnson & Johnson is probably a good investment for investors seeking stability and a bond-like investment.
J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?
A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.
